The European Union has approved Sanofi’s blockbuster drug Dupixent for the treatment of chronic obstructive pulmonary disease , the French pharmaceutical giant said on Wednesday.
The EU’s European Medicines Agency “is the first regulatory authority in the world to approve Dupixent for COPD patients,” it added. According to phase 3 trials, the drug reduced the rate of exacerbations by more than 30 per cent in patients with type two inflammation over 52 weeks.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: